



1615 / 1FW





CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)		Docket No.	
Applicant(s): Alvaro et al.		PI4748USW	
Serial No. 10/502,261	Filing Date July 22, 2004	Examiner	Group Art Unit 1615

Invention: Piperidine Derivatives And Their Use As Antagonists Of Tachykinins

I hereby certify that this Supplemental IDS w/references
(Identify type of correspondence)
is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on February 22, 2005
(Date)

Valerie L. Phillips
(Typed or Printed Name of Person Mailing Correspondence)

(Signature of Person Mailing Correspondence)





014748USW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Alvaro et al.

Intl. Serial No.: 10/502,261

Group Art Unit: 1615

Intl. File Date: July 22, 2004

Examiner:

For: Piperidine Derivatives And Their Use As Antagonists Of Tachykinins

Director of the U.S. Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references are enclosed: References 23-35, 61-85
☐ Copies of the references were submitted in parent application Serial No. _____. (37 CFR 1.98(d))
☐ A copy of the International Search Report which issued on International Application No. PCT/GB03/00501 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

- B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
- (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311, whichever occurs first.

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.


In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Lorie Ann Morgan

Registration No. 38,181

Date:

2 Feb 05

GlaxoSmithKline

Corporate Intellectual Property

5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8222

Facsimile: (919) 483-7988

FORM PTO-101P INFORMATION DISCLOSURE STATEMENT FEB 07 2005				ATTORNEY DOCKET NO. PI4748USW		SERIAL NO. 10/502,261	
				APPLICANT: Alvaro et al.			
				FILING DATE: 7/22/04		GROUP 1615	
U.S. PATENT DOCUMENTS							
Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate	
	1	5,710,169	Jan. 20, 1998	Russell et al.			
	2	5,998,444	Dec. 7, 1999	Russell et al.			
	3	6,147,083	Nov. 14, 2000	Russell et al.			
	4	5,028,610	July 2, 1991	Hirai et al.			
	5	6,197,772	March 6, 2001	Janssens et al.			
	6	6,521,621	Feb. 18, 2003	Janssens et al.			
	7	RE 37,886	Oct. 15, 2002	Janssens et al.			
	8	5,696,123	Dec. 9, 1997	Dollinger et al.			
	9	5,708,006	Jan. 13, 1998	Dollinger et al.			
	10	5,985,881	Nov. 16, 1999	Dollinger et al.			
	11	6,191,135	Feb. 20, 2001	Dollinger et al.			
	12	6,235,732	May 22, 2001	Dollinger et al.			
	13	6,090,807	July 18, 2000	Hellendahl et al.			
	14	6,057,323	May 2, 2000	Zhang et al.			
	15	5,563,127	Oct. 8, 1996	Amparo et al.			
	16	5,698,538	Dec. 16, 1997	Amparo et al.			
	17	5,348,955	Sept. 20, 1994	Greenlee et al.			
	18	5,109,014	Apr. 28, 1992	Jacobson et al.			
	19	5,538,982	July 23, 1996	Hagan et al.			
	20	5,859,015	Jan. 12, 1999	Graham et al.			
	21	6,319,953	Nov. 20, 2001	Carlson et al.			
	22	6,642,240	Nov. 2003	Alvaro et al.			
Continue on page <u>2</u>							
FOREIGN PATENT DOCUMENTS							
	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No	
	23	WO 97/32865	Sept. 12, 1997	WIPO			
	24	WO 98/57954	Dec. 23, 1998	WIPO			
	25	WO 01/25219	Apr. 12, 2001	WIPO			
	26	WO 95/00498	Jan. 5, 1995	WIPO			
	27	WO 02/057233	July 25, 2002	WIPO			
	28	WO 02/032867	Apr. 25, 2002	WIPO			
	29	WO 98/01133	Jan. 15, 1998	WIPO			Abstract only
	30	WO 96/03378	Feb. 8, 1996	WIPO			Abstract only
Continue on page <u>2</u>							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	31	Davis, David T., "Synthesis A. Biological Activity of a Series of Piperazin-2, 3-Biones," Journal of Antibiotics, Vol. XLII, No. 3, 1989, pp. 367-73.					
	32	Rupniak et al. "Differential inhibition of foot tapping and chromodacyorrhoea in gerbils by CNS penetrant and non-penetrant tachykinin NK ₁ receptor antagonists." European Journal of Pharmacology 265:179-183 (1994).					
	33	Megens, A., et al. J. Pharmacology and Experimental Therapeutics 302(2):696-709 (2002).					
	34	Challet, E., et al. Neuropharmacology 40(3):408-415 (2001).					
	35	Romerio, et al. Clinical Pharmacology and Therapeutics 66(5):522-527 (1999).					
Continue on page _____							
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

FORM PTO-M49 INFORMATION DISCLOSURE STATEMENT <div style="text-align: center; margin-top: 10px;"> FEB 3 7 2005 </div>				ATTORNEY DOCKET NO. PI4748USW		SERIAL NO. 10/502,261	
				APPLICANT: Alvaro et al.			
				FILING DATE: 7/22/04		GROUP 1615	
U.S. PATENT DOCUMENTS							
Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate	
	36	4,308,387	Dec. 29, 1981	Bjork et al.			
	37	4,110,327	Apr. 29, 1978	Saikawa et al.			
	38	4,379,152	Apr. 5, 1983	Saikawa et al.			
	39	4,087,424	May 2, 1978	Saikawa et al.			
	40	4,112,090	Sept. 5, 1978	Saikawa et al.			
	41	4,410,522	Oct. 18, 1983	Saikawa et al.			
	42	4,219,554	Aug. 26, 1980	Saikawa et al.			
	43	4,327,097	Apr. 27, 1982	Saikawa et al.			
	44	5,756,504	May 26, 1998	Bock et al.			
	45	5,464,788	Nov. 7, 1995	Bock et al.			
	46	5,334,606	Aug. 2, 1994	MacLeod et al.			
	47	5,360,820	Nov. 1, 1994	Hagan et al.			
	48	5,716,942	Feb. 10, 1998	Dorn et al.			
	49	5,952,315	Sept. 14, 1999	Baker et al.			
	50	5,977,104	Nov. 2, 1999	Baker et al.			
	51	6,114,315	Sept. 5, 2000	Baker et al.			
	52	6,117,855	Sept. 12, 2000	Carlson et al.			
	53	6,191,139	Feb. 20, 2001	Hagan et al.			
	54	5,883,096	Mar. 16, 1999	Lowe et al.			
	55	6,037,352	Mar. 14, 2000	Lowe et al.			
	56	6,288,068	Sept. 11, 2001	Lowe et al.			
	57	5,814,636	Sept. 29, 1998	Katano et al.			
	58	5,935,951	Aug. 10, 1999	Ofner et al.			
	59	US 20020103205	Aug. 1, 2002	Lowe et al.			
	60	5,576,317	Nov. 19, 1996	Gonsalves et al.			
Continue on page _____							
FOREIGN PATENT DOCUMENTS							
	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No	
	61	EP 0721941	July 17, 1996	EUROPE			
	62	WO 97/16440	May 9, 1997	WIPO			
	63	WO 92/16211	Oct. 1, 1992	WIPO			
	64	WO 99/26921	June 3, 1999	WIPO			
	65	WO 96/14844	May 23, 1996	WIPO			
	66	WO 96/20173	July 4, 1996	WIPO			
	67	EP 718287	Dec. 19, 1995	EUROPE			
	68	WO 99/09985	Mar. 4, 1999	WIPO			
	69	WO 97/36889	Oct. 9, 1997	WIPO			
	70	WO 97/36888	Oct. 9, 1997	WIPO			
	71	WO 97/36592	Oct. 9, 1997	WIPO			
	72	WO 95/25443	Sept. 28, 1995	PCT			
	73	EP 293532	Oct. 15, 1987	EP			
	74	WO 98/20001	May 14, 1998	WIPO			
Continue on page <u>3</u>							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
Continue on page _____							
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

